Larimar Therapeutics, Inc. (LRMR) — 8-K Filings

8-K Filings (22)

• 8-K Filing — Dec 17, 2025
• 8-K Filing — Nov 10, 2025
• Larimar Therapeutics Files 8-K — Oct 14, 2025 Risk: low
  On October 14, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" an
• Larimar Therapeutics Files 8-K — Sep 29, 2025 Risk: low
  On September 29, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. Larimar The
• Larimar Therapeutics Files 8-K with Material Agreement — Jul 31, 2025 Risk: medium
  On July 29, 2025, Larimar Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and ex
• Larimar Therapeutics Files 8-K Report — Jul 29, 2025 Risk: medium
  On July 29, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific details r
• Larimar Therapeutics Files 8-K — Jun 23, 2025 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The company, formerly known as Zafgen, Inc., is incor
• Larimar Therapeutics Files 8-K on Shareholder Votes — May 13, 2025 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on May 13, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details a
• Larimar Therapeutics Files 8-K — May 5, 2025 Risk: low
  On May 5, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific m
• Larimar Therapeutics Appoints New CEO, Board Member — Jan 27, 2025 Risk: medium
  Larimar Therapeutics, Inc. announced on January 22, 2025, the appointment of Brian R. Markison as Chief Executive Officer and a member of the Board of Directors
• Larimar Therapeutics Files 8-K — Jan 10, 2025 Risk: low
  On January 10, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at Three Bala Pl
• Larimar Therapeutics Files 8-K — Dec 16, 2024 Risk: low
  On December 16, 2024, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no spec
• Larimar Therapeutics Files 8-K — Nov 18, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The company, formerly known as Zafgen, Inc., is i
• Larimar Therapeutics Files 8-K — Aug 7, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, as well as other events and financial
• Larimar Therapeutics Files 8-K Report — Jun 10, 2024 Risk: low
  On June 10, 2024, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statement
• Larimar Therapeutics Files 8-K on Shareholder Vote Matters — May 31, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on May 31, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The company, formerly
• Larimar Therapeutics Files 8-K — May 30, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is incorp
• Larimar Therapeutics Files 8-K — May 20, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on May 20, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is incorp
• Larimar Therapeutics Files 8-K — Mar 11, 2024 Risk: low
  Larimar Therapeutics, Inc. filed an 8-K on March 11, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is inco
• Larimar Therapeutics Enters Material Definitive Agreement — Feb 16, 2024 Risk: medium
  Larimar Therapeutics, Inc. filed an 8-K on February 16, 2024, reporting an "Entry into a Material Definitive Agreement" on February 14, 2024. The filing indicat
• Larimar Therapeutics Terminates Material Definitive Agreement — Feb 14, 2024 Risk: medium
  Larimar Therapeutics, Inc. filed an 8-K on February 14, 2024, to report the termination of a material definitive agreement. The earliest event related to this t
• Larimar Therapeutics Files 8-K on Financials & Other Events — Feb 12, 2024 Risk: medium
  Larimar Therapeutics, Inc. filed an 8-K on February 12, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing i

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX